Sydney Rosen from the Center for Global Health and Development at Boston University provided a thoughtful overview of the evidence and the key issues relevant to linkage to and continuity in care for HIV infected persons during the pre-antiretroviral therapy (ART) period. She presented Wednesday at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) […]
Chris Beyrer, MD, MPH, from Johns Hopkins University offered an elegant overview of the epidemiology of the HIV epidemic among men who have sex with men (MSM) in low- and middle-income countries during a symposium at the 18th Conference on Retroviruses and Opportunistic Infections on Monday entitled “Responding to Risk”. This meta-analysis looked at four […]
Rochelle Walensky, MD, MPH, who has published widely on the cost effectiveness of HIV interventions domestically and globally, offered a plenary presentation on the subject at the 18th Conference on Retroviruses and Opportunistic Infections in Boston Tuesday morning. The World Health Organization (WHO) has developed criteria that calls a cost-per-year-of-life-saved that is less than or […]
Early-phase study reports looking at the use of a microbicidal tenofovir gel proven to reduce HIV infection during vaginal sex have shown promising results when used rectally. The study results were presented at the 18th Conference on Retroviruses and Opportunistic Infections in Boston Monday. A strong antiviral effect was achieved when the gel was used […]
Anthony Harries, MD, offered a powerful overview of the history of the global AIDS response from the vantage point of his work over more than a decade in the small African country of Malawi. He spoke at the plenary session of the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston Sunday. Malawi is a […]
HIV
Dr. Manasseh Phiri was working at the Centre for Infectious Disease Research in Zambia when I met him 10 years ago, although his days as a […]
Tuberculosis
In sub-Saharan Africa where the odds of dying within a year of starting treatment for HIV can still hover close to one-in-10, diagnosing and treating TB […]
Research & Development
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
The following is a guest post by Heather B. Davis, MPH, and Emily A. Bobrow, PhD, MPH, of MEASURE Evaluation Who has a strategic interest in […]